Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Avatrombopag
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Pronunciation | a" va trom' boe pag |
Trade names | Doptelet |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618032 |
License data |
|
Pregnancy category |
|
Routes of administration |
By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C29H34Cl2N6O3S2 |
Molar mass | 649.65 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) |
Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in May 2018, the European Union in June 2019, and Australia in January 2023.
It acts as a thrombopoietin receptor agonist.
External links
- "Avatrombopag". Drug Information Portal. U.S. National Library of Medicine.
Antihemorrhagics (coagulation) |
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Antifibrinolytics |